Table V.
Attainment of LDL-C therapeutic goals depending on the CV risk and ≥ 50% reduction in LDL-C concentration among subpopulations treated with statin monotherapy or in combination with ezetimibe according to statin dose
| Type of therapy regimen | Dose of statins | Attainment of LDL-C < 1.8 mmol/l N (%)* | Attainment of LDL-C < 2.6 mmol/l N (%)* | Attainment of therapeutic goal: ≥ 50% reduction in LDL-C N (%)* | |
|---|---|---|---|---|---|
| Very high CV risk | High CV risk | Very high CV risk | High CV risk | ||
| Statin monotherapy | 4 (28.6) | 29 (37.7) | 8 (57.1) | 44 (57.1) | |
| Statin monotherapy | High | 3 (27.3) | 11 (39.3) | 6 (54.5) | 18 (64.3) |
| Moderate | 1 (33.3) | 17 (37.8) | 2 (66.7) | 25 (55.6) | |
| Low | 0 (0) | 1 (25.0) | 0 (0) | 1 (25.0) | |
| Statin in combination with ezetimibe | 1 (3.8) | 17 (23.3) | 18 (69.2) | 43 (58.9) | |
| Statin in combination with ezetimibe | High | 1 (5.3) | 10 (19.2) | 14 (73.7) | 33 (63.5) |
| Moderate | 0 (0) | 6 (30.0) | 4 (57.1) | 9 (45.0) | |
| Low | 0 (0) | 1 (100.0) | 0 (0) | 1 (100.0) | |
*
The percentages in parentheses represent the prevalence of patients with target levels of LDL-C in CV risk subpopulations on particular therapy regimens.